Business context and reporting period
Entity mismatch: The supplied filing is Synta Pharmaceuticals Corp.’s unaudited Form 10-Q for the quarter ended March 31, 2016—not a Madrigal Pharmaceuticals, Inc. filing. Synta was a development-stage biotechnology company with no approved or marketed products. After terminating its Phase 3 GALAXY-2 trial for futility, it substantially reduced its workforce and research activity while evaluating strategic alternatives.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.4 million | $16.2 million |
| General and administrative expense | $3.0 million | $4.2 million |
| Operating loss | $6.4 million | $20.3 million |
| Net loss | $6.5 million | $20.7 million |
| Net loss per share | $0.05 | $0.19 |
| Cash used in operating activities | $12.2 million | $18.8 million |
No product revenue was reported, so a revenue margin is not meaningful. At March 31, cash and cash equivalents were $42.8 million and marketable securities were $9.2 million, totaling approximately $52.0 million (fair value: $52.042 million), versus $66.6 million at December 31, 2015. Working capital was $44.0 million. Total assets were $53.0 million and total liabilities were $8.6 million.
Cash from investing activities was $22.4 million, primarily reflecting $31.6 million of marketable-security maturities less $9.2 million of purchases; financing activities used $2.3 million for loan principal payments. The reported $7.8 million increase in cash therefore reflects, in part, movements between cash and marketable securities. Term-loan principal remaining was about $2.3 million due by June 2016 under the GECC loan and $49,000 due by July 2016 under the Oxford loan. GECC also had a $788,000 exit fee due with the final principal payment. Rates were 9.75% and 13.35%, respectively.
Material changes versus the prior period
- Total operating expenses fell 68% year over year, mainly as research and development expense declined 79%, including an 87% reduction in ganetespib costs after GALAXY-2 ended and other trials were wound down.
- General and administrative expense declined 27%; net loss narrowed by about $14.2 million. Interest expense also fell, reflecting loan repayments.
- Two restructurings followed the GALAXY-2 outcome. The February 2016 workforce reduction eliminated 23 positions, including 19 R&D roles, leaving 10 employees; the company discontinued a substantial portion of R&D activity.
- In January 2016, Synta transferred elesclomol development under an asset purchase arrangement in exchange for a minority interest, potential development milestones, and potential royalties.
Outlook, transaction, and key risks
- On April 13, 2016, Synta and Madrigal entered a merger agreement. Synta planned to issue approximately 253.9 million shares to Madrigal holders; after closing, existing Synta holders were expected to own about 36% of the combined company and former Madrigal holders about 64%. The anticipated third-quarter 2016 closing was subject to conditions, including Synta stockholder approval and at least $28.5 million of net cash. The filing does not establish that the transaction subsequently closed.
- The proposed combined company was intended to focus on cardiovascular-metabolic disease and NASH. Madrigal’s MGL-3196 was described as Phase 2-ready. Synta said it did not expect to raise additional funds before the merger, but stated the transaction was not assured.
- Management expected March 31 cash, cash equivalents, and securities, together with lower costs, to fund operations for at least 12 months, assuming no new partnership, equity financing, or ATM sales. If the merger failed, Synta could need significant additional funding sooner, pursue another transaction, or consider liquidation.
- Management anticipated lower R&D spending, but higher 2016 G&A costs from merger expenses and facilities overhead reallocation, partly offset by restructuring savings. The company expected no immediate IND submission for STA-12-8666 and planned only limited support for two ongoing investigator-sponsored ganetespib trials.
- Risks included merger failure, dilution and reduced influence for Synta holders, transaction costs, Nasdaq listing requirements, no product revenue, continued losses, and limited internal research capacity. The filing also disclosed a possible $1.25 million termination fee or reimbursement of up to $250,000 in certain circumstances if the merger agreement ended.
- Synta reported effective disclosure controls and no material legal proceedings. Its April 2016 lease termination required an approximately $213,000 final payment and ended future rent obligations under that lease.
Most important facts to verify
- Confirm the intended issuer: this filing is for Synta, not Madrigal.
- Verify whether the merger closed, its final share issuance and ownership split, and whether the $28.5 million minimum-cash condition was met.
- Check post-quarter cash use, restructuring and merger costs, and whether management’s 12-month runway estimate remained valid.
- Confirm repayment of the remaining loans and GECC exit fee, and review any related covenant or security-interest implications.
- Review the status of Nasdaq listing compliance. The supplied filing text shows the May 6, 2016 closing bid price as “$xx,” so it does not provide a clear value.